Methylphenidate
- Generic Name
- Methylphenidate
- Brand Names
- Adhansia, Aptensio, Biphentin, Concerta, Cotempla, Daytrana, Foquest, Jornay, Metadate, Methylin, Quillichew, Quillivant, Relexxii, Ritalin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19NO2
- CAS Number
- 113-45-1
- Unique Ingredient Identifier
- 207ZZ9QZ49
- Background
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve ...
- Indication
Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy
- Associated Therapies
- -
The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD
- Conditions
- Interventions
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- VU University of Amsterdam
- Target Recruit Count
- 61
- Registration Number
- NCT02501798
- Locations
- 🇳🇱
Vrije Universiteit Amsterdam, Amsterdam, Netherlands
EAA/Therapy for Treating Children With ADHD
- Conditions
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT02482649
- Locations
- 🇰🇷
Yoo-Sook Joung, Seoul, Korea, Republic of
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance
- Conditions
- Interventions
- First Posted Date
- 2015-06-22
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Region Västmanland
- Target Recruit Count
- 39
- Registration Number
- NCT02477280
- Locations
- 🇸🇪
Landstinget Västmanland, Västerås, Sweden
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Region Västmanland
- Target Recruit Count
- 40
- Registration Number
- NCT02473185
- Locations
- 🇸🇪
Landstinget Västmanland, Västerås, Sweden
Stimulant Effects on Brain Activity
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 19
- Registration Number
- NCT02453698
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Neuroendocrine Substrates, Candidate Genes and Endophenotypes in ADHD
- Conditions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02392169
- Locations
- 🇨🇳
Liang-Jen Wang, Kaohsiung, Taiwan
Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT02361125
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Effects of Atx and Oros-mph on Executive Functions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- TC Erciyes University
- Target Recruit Count
- 43
- Registration Number
- NCT02352051
The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder
- Conditions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 46
- Registration Number
- NCT02344784
- Locations
- 🇮🇱
The mental health clinic for children and adolescents at the HaEmek Medical Center, Afula, Israel
Apathy in Dementia Methylphenidate Trial 2
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 200
- Registration Number
- NCT02346201
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇺🇸Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸University of Arkansas, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.